Erschienen in:
27.04.2017 | Original articles
Transcatheter vs. surgical aortic valve replacement and medical treatment
Systematic review and meta-analysis of randomized and non-randomized trials
verfasst von:
A. Ak, I. Porokhovnikov, F. Kuethe, P. C. Schulze, M. Noutsias, Prof. Dr. P. Schlattmann
Erschienen in:
Herz
|
Ausgabe 4/2018
Einloggen, um Zugang zu erhalten
Abstract
Background
Transcatheter aortic valve replacement (TAVR) has emerged as the procedure of choice for patients with severe aortic stenosis (AS) and high perioperative risk. We performed a meta-analysis to compare the mortality related to TAVR with medical therapy (MT) and surgical aortic valve replacement (SAVR).
Methods
A systematic literature search was conducted by two independent investigators from the database inception to 30 December 2014. Relative risk (RR) and odds ratio (OR) were calculated and graphically displayed in forest plots. We used I
2 for heterogeneity (meta-regression) and Egger’s regression test of asymmetry (funnel plots).
Results
We included 24 studies (n = 19 observational studies; n = 5 randomized controlled trials), with a total of 7356 patients in this meta-analysis. Mean age had a substantial negative impact on the long-term survival of AS patients (OR = 1.544; 95% CI: 1.25–1.90). Compared with MT, TAVR showed a statistically significant benefit for all-cause mortality at 12 months (OR = 0.68; 95% CI: 0.49–0.95). Both TAVR and SAVR were associated with better outcomes compared with MT. TAVR showed lower all-cause mortality over SAVR at 12 months (OR = 0.81; 95% CI: 0.68–0.97). The comparison between SAVR and TAVR at 2 years revealed no significant difference (OR = 1.09; 95% CI: 1.01–1.17).
Conclusion
In AS, both TAVR and SAVR provide a superior prognosis to MT and, therefore, MT is not the preferred treatment option for AS. Furthermore, our data show that TAVR is associated with lower mortality at 12 months compared with SAVR. Further studies are warranted to compare the long-term outcome of TAVR versus SAVR beyond a 2-year follow-up period.